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(A) HCT116 and SW620 cells were treated with vehicle (Control), 1M selumetinib (SEL), 1M of the PI3K inhibitor GDC0941 (GDC), or the combination for 72h and viable cell titer was determined by Cell TiterGlo Assay. Values represent the change in viable cell number relative to starting cell titer immediately before treatment. (B) Cells were treated as in (A) for 72 hours and the percentage of apoptotic cells was determined by Annexin V staining. Asterisks represent p<0.001 for the combination group vs. all other groups by one-way ANOVA with Tukey post-hoc test. (C) shRNA hits were selected using 2 criteria. A shRNA was scored as a hit if it showed: (1) a 2-fold or greater decrease in abundance in the MEK inhibitor-treated population (MEKi) vs. the vehicletreated population, AND (2) a 2-fold or greater decrease in abundance in the MEK inhibitor-treated vs. the initial population. 145 hits were identified in HCT116 cells, and 50 hits were identified in SW620 cells. The 17 hits that were common to both cell lines are shown. BCL-XL (BCL2L1) is indicated with an arrow. (D) Validation studies for the top 8 hits are shown. HCT116 and SW620 cells were infected with three independent shRNAs for each gene candidate. After 48 h of puromycin selection, cells were treated with vehicle or 1M selumetinib for an additional 72 h, and cells were stained with crystal violet. Values shown represent the ratio of the fold-decrease in cell titer for each shRNA in the presence of selumetinib (relative to shGFP-infected cells treated with selumetinib) to the fold-decrease in cell titer in the presence of vehicle only (relative to shGFP-infected cells treated with vehicle only). Thus, shRNAs with values to the right of the y-axis produce a greater decrease in cell viability in the presence of selumetinib than in its absence. Each dot represents the mean value for each shRNA. Vertical hash marks represent the mean of all three shRNAs for a given gene target, and error bars represent SEM. and selumetinib (25mg/kg twice daily) for the specified times, and the percent regression in lung tumor volume (relative to starting tumor volume) is shown for individual mice. (C) Serial MRI scans of one mouse treated for 7 weeks with ABT-263/selumetinib. Red arrows indicate dense areas of lung tumor in the pre-treatment images. (D) Established lung tumors induced by adenoviral-Cre inhalation in LSL-KRAS G12D mice (KRAS) and LSL-KRAS G12D ; p53 lox/lox mice (KRAS-p53) were treated with the combination of ABT-263 (100mg/kg daily) and selumetinib (25mg/kg twice daily). The best overall response during treatment, represented by the percent regression in lung tumor volume (relative to starting tumor volume) is shown. Each bar represents the percent regression for an individual mouse. (E) HCT116 and SW620 xenografts were treated with vehicle for 3 days or with the combination of ABT-263 (100mg/kg daily) and selumetinib (25mg/kg twice daily) for 3 days or for 21-28 days, as indicated. Tumors were harvested and P-ERK levels were assessed by western blot. Figure 3) : Gene Set Enrichment Analysis (GSEA) of genes correlating with sensitivity to ABT-263/AZD6244. GSEA was performed using the genes identified in Figure 3A . Top 10 enriched gene sets are shown, ranked by p-value. Gene sets related to epithelial vs. mesenchymal differentiation are shown in red.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Cell Lines and Reagents
All cell lines were grown in DMEM/F12 (GIBCO) with 10% FBS and assayed in DMEM/F12 with 5% FBS and were obtained from the Massachusetts General Hospital 
Western Blot Analysis, Immunoprecipitation, and Antibodies
Western blotting was performed using standard methods. After treatment with indicated drugs, cells were washed with cold PBS and lysed in the following lysis buffer: 20 mM Tris pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 5 mM sodium pyrophosphate, 50 mM NaF, 10 nM -glycerophosphate, 1 mM sodium vanadate, 0.5 mM DTT, 4 g/mL leupeptin, 4 g/mL pepstatin, 4 g/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride. Lysates were centrifuged at 16,000 x g for 5 min at 4°C. Protein concentrations were determined by BCA assay (Thermo Scientific). Proteins were resolved by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Hybond-P, Amersham). Immunoblotting was performed per antibody manufacturer's specifications.All antibodies were purchased from Cell Signaling, except for GAPDH (Millipore), E-cadherin (BD Bioscience), and MCL-1 and Zeb1 (Santa Cruz Biotechnology). For immunoprecipitation experiments, cells were lysed using the same lysis buffer as above and immunoprecitpiated with anti-BIM antibody (Cell Signaling #2819) and Protein A sepharose (GE Healthcare) after incubation overnight at 4 o C. The immunoprecipitate, the supernatant, and a sample of the initial whole cell lysate for each condition were then analyzed by western blot.
Determination of Cell Titer
Cells were seeded at 2,000 cells per well in parallel 96-well plates. After overnight incubation, one plate was frozen immediately to represent the starting cell titer, and the other plate was treated in for 72h (six wells per condition) and then frozen. Plates were thawed simultaneously, and cell titer was determined using Cell Titer Glo assay (Promega) according to the manufacturer's protocol. Change in cell titer for each treatment condition was calculated relative to starting cell titer.
Annexin V Apoptosis Assays
Cells were seeded at ~30-40% confluence in 6cm plates. After overnight incubation, media was aspirated and replaced with media with or without various concentrations of indicated drugs. After 72h, media was collected. Cells were washed with PBS and trypsinized. PBS wash and trypsinized cells were added to the collected media in a single tube. Cells were pelleted, washed once with PBS and resuspended in Annexin binding buffer (BD Biosciences) at ~1 x 10 6 cells/mL. Cells were stained with propidium iodide (BD Biosciences) and Annexin V Cy5 (Biovision) according to the manufacturer's protocol and assayed on a LSRII flow cytometer (BD Biosciences).
Immunohistochemistry
IHC on formalin-fixed paraffin-embedded tissue was performed for P-ERK as previously described (Engelman et al., 2008 
Pooled shRNA screen and analysis
Lentivital pooled shRNA library was constructed using a subset of the RNA Consortium (TRC) shRNA library targeting "druggable" genes, such as kinases and regulators of cell proliferation and survival using previously described techniques, available at www.broad.mit.edu/rnai/trc (Moffat et al., 2006; Luo et al., 2008; Barbie et al., 2009) . 3 x 10 6 target cells were infected with the pooled lentiviral library at a multiplicity of infection of 0.3, and the morning after infection, cells were selected in 2g/mL puromycin for 48 h to eliminate uninfected cells. Cells were split into three aliquots of ~1.5 x 10 6 cells. One aliquot was immediately frozen to represent the initial population. The remaining two aliquots were seeded into two separate 15 cm plates. The following day, media with 5% FBS containing DMSO vehicle or 1M selumetinib was added, and cells were cultured for 7 days. Fresh media and drug was added after day 3.
At all times, sufficient cell numbers were used so that an average of at least 200 cells per shRNA were maintained. After 7 days, cells were trypsinized, pelleted, and frozen.
Genomic DNA was isolated from the initial cell aliquot and the vehicle and selumetinib- The abundance of each shRNA sequence was quantified in terms of number of individual shRNA sequence reads per one-million total reads. The ratio of the abundance of each shRNA in MEK inhibitor-treated samples vs. both the vehicle-treated and initial samples was calculated. For each cell line, a given shRNA was considered a "hit" if that shRNA showed a decrease in abundance of at least 2-fold relative to both the vehicletreated and initial samples. These criteria were chosen to select shRNAs that not only illustrated enhanced effect in the presence of MEK inhibitor, but also that caused the most profound suppression of cell number in the presence of MEK inhibitor relative to the initial population.
Microarray analysis
Available expression profiles for KRAS-mutant cell lines were obtained from the Cancer Cell Line Encyclopedia web site www.broadinstitute.org/ccle using the GENE-E tool and the CCLE_Expression_Entrez_2012-04-06.res data file for 18988 probe IDs (Barretina et al., 2012) . Cell lines were divided into two groups based on percent apoptosis induced by ABT-263/selumetinib with 25% as the threshold for sensitivity.
This threshold was chosen since 90% of cell lines showed <25% apoptosis induction in the presence of selumetinib alone. The prediction analysis for microarrays module for R (PAMR) was used to create a list of differentially expressed genes (Tibshirani et al., 2002) . A threshold of 3 was used as this gave the lowest cross-validation error rate and had a false discovery rate of <0.2. Average linkage hierarchical clustering was performed on this list using Cluster/Treeview to generate a heatmap (Eisen et al., 1998) .
Gene Set Enrichment Analysis (GSEA) was performed on the gene list identified through the PAMR algorithm as above using GSEA software available at www.broadinstitute.org/gsea (Mootha et al., 2003; Subramanian et al., 2005) .
Lentiviral shRNA experiments
shRNA constructs in the pLKO.1 lentiviral vector containing the following targeting sequences were used:
shGFP: 5'-GCAAGCTGACCCTGAAGTTCAT-3' shBCL-XL#1: 5'-GCTCACTCTTCAGTCGGAAAT -3'
